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Abstract
Loss to follow-up (LF), which refers to patients who started care but voluntary stopped it, is a problem for patients with chronic
disease. We aimed to estimate the rate of LF among patients seropositive for hepatitis C virus (HCV) and identify possible
demographic and lifestyle risk factors associated with LF. From January 2009 through December 2012, 1010 anti-HCV-positive
patients were included in the study. Among participants, 223 (22.1%) met the case definition for LF (more than 1-year elapsed
since the last clinical appointment). Among 787 patients who remained in follow-up, 372 (47.2%) were discharged after
undetectable HCV RNA, 88 (11.1%) were transferred (and remained on regular follow-up at the destination), and 25 (3.1%) died.
According to univariate analysis, male gender, absence of a life partner, black race, psychiatric illness, previous alcohol abuse,
previous or current recreational drug use, and previous or current smoking were significantly associated with LF. In multivariate
analysis, absence of a life partner (adjusted odds ratio (AOR)=1.44; 95% confidence interval (95%CI)=1.03–2.02), black race
(AOR=1.81, 95%CI=1.12–2.89), psychiatric illness (AOR=1.77, 95%CI=1.14–2.73), and the presence of at least one lifestyle
risk factor (pertaining to substance abuse) (AOR=1.95, 95%CI=1.29–2.94) were independently associated with LF. Our study
provides an estimate of the incidence of LF among anti-HCV-positive patients and identifies risk factors associated with this
outcome. In addition, these results can help clinicians recognize patients at risk for LF, who require additional support for the
continuity of care.
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Introduction
Hepatitis C is the leading cause of liver disease world-
wide and currently 20–30% of individuals with chronic
hepatitis C develop cirrhosis. By 2030 this rate is expected
to rise to 45% (1,2). Among patients with hepatitis C and
cirrhosis, the annual risk of hepatocellular carcinoma
(HCC) is 3–5%. With the new direct-acting agents against
hepatitis C virus (HCV) infection, sustained virological
response (SVR) is possible in over 80% of cases. SVR
is associated with increased survival and a significant
reduction in complications such as hepatocellular carci-
noma and hepatic decompensation (3,4). However, the
successful treatment of patients with chronic hepatitis C
and prevention of further complications require regular
medical follow-up.
Loss to follow-up (LF), which refers to patients who
started care but voluntarily stopped it, is a problem
for patients with chronic disease. (5,6). There has not
been any study in the HCV-infected population in Brazil
specifically designed to assess LF rates and few are
available worldwide, so the magnitude of this problem
remains unknown. In addition, little is known about risk
factors associated with LF in patients with HCV infection in
outpatient settings.
A clear understanding of how patient characteristics
influence LF can assist treatment programs to institute
measures for improving patient adherence directed at
those with increased risk for interruption of follow-up, such
as intensified outreach or follow-up services.
We aimed to identify the rate of LF in outpatients
positive for antibodies against HCV (anti-HCV), and
demographic and lifestyle risk factors associated with LF.
Material and Methods
Study population
Anti-HCV-positive patients from a public regional
outpatient clinic for viral hepatitis in the city of Campinas,
São Paulo State, Southeast region of Brazil were included
in this study. Patients enrolled in the study started care
from January 2009 to December 2012. Samples were
tested against HCV antibodies using Abbott AxSYM Anti-
HCV 3.0 (Abbott Laboratories, Germany). Quantitative
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serum HCV RNA was assessed by Amplicor HCV 2
(Roche Diagnostics Systems Inc., USA) upon entry into
care in order to confirm chronic hepatitis C infection.
Data collection
We collected patient data using standardized ques-
tionnaires indicated by healthcare providers filled dur-
ing the first visit to the clinic. The questionnaire included
demographics information and medical history with
special emphasis on comorbidities and lifestyle. Lifestyle
encompassed previous or current alcohol abuse, previous
or current recreational drug use, and tobacco smoking.
Alcohol abuse was defined as seven or more drinks per
week. Current alcohol abuse, illicit drug use, and smoking
were considered active, if it occurred during the six
months prior to study enrollment, and previous, if
discontinued before that period. In case of LF, a second
questionnaire was used for collecting information regard-
ing reasons for care interruption. All information collect
was entered into EPI INFO 2000 (Centers for Disease
Control and Prevention, USA).
Definition of loss to follow-up
We defined LF as patients with more than 1 year since
last clinic appointment. When patients presented more
than one interruption during the study period, only the
first episode was considered for analysis. LF rate was
calculated using the number of LF events divided by the
total number of patients who started treatment during the
study period. Patients transferred to other health facilities
were not considered as LF.
When patients interrupted clinic visits for over 12 months,
a recall was attempted through available contact informa-
tion. We also reviewed medical records to locate informa-
tion related to death, hospital transfers, and any other
relevant data.
Factors associated with LF
We compared the characteristics of patients who inter-
rupted care with patients who attended the clinic regularly
during the study period to identify factors associated with
follow-up interruption. Demographic data included age
at enrollment, gender, and race. Lifestyle data included
previous or current alcohol abuse, recreational drug use,
and tobacco smoking.
Statistical analyses
Continuous variables are reported as means and
standard deviations, and categorical variables as frequen-
cies, unless otherwise stated. The X2 test was used for
nominal categorical variables. Analysis of variance (stan-
dard or nonparametric, as appropriate) was used to test
associations between continuous and categorical vari-
ables. Variables for which an association was suspected
in the univariate analysis (i.e., Pp0.20) were included in a
stepwise logistic regression model. All analyses were
performed with EPI INFO 2000. A significance level of 5%
(Po0.05) was used throughout.
Ethical considerations
This study is the result of a retrospective evaluation of
medical records of patients treated at a municipal clinic
under routine care, and it was approved by the Ethical
Committee of the "Centro Infantil de Investigac¸ões Hema-
tológicas Dr. Domingo A. Boldrini" (process #39002414.5.
0000.5376). Patient informed consent was not deemed
necessary for this study.
Results
Between March 1 and December 31, 2012, 1010 anti-
HCV-positive patients started care in this outpatient clinic.
Patient characteristics are show in Table 1. Among all
patients, 55.1% were male and the mean age at the
beginning of follow-up was 49 years. Information about
race was available for 987 (97.7%) patients of which
11.1% were black. Almost 45% (444/992) of patients
reported not having a life partner, such as spouse or
domestic partner. In regards to comorbidities, information
was available for 943 patients, of which 136 (14.4%)
reported diabetes and 40 (13.4%), psychiatric disorders.
Moreover, self-reported information on lifestyle risk factors
was available for 979 patients with 657 (67.1%) who had
at least one lifestyle risk factor. The most common lifestyle
risk factor was current or previous alcohol consumption
(n=495; 50.6%) and current tobacco smoking (n=442;
41.4%). Among all enrolled patients, when LF occurred,
576 (57.0%) had detectable serum HCV RNA, 372
(36.8%) had undetectable serum HCV RNA, and the
remaining 62 (6.1%) patients were lost to follow-up before
Table 1. Characteristics of the 1010 anti-HCV-positive patients.
Characteristic Total* n (%)
Male gender 1010 557 (55.1)
Age (years) (mean ±SD) 1010 48.3±12.47
Black race 987 110 (11.1)
Absence of a life partner 992 444 (44.8)
Presence of comorbidity 943 545 (57.8)
Diabetes 943 136 (14.4)
Psychiatric illness 943 126 (13.4)
Presence of X1 lifestyle factor 979 657 (67.1)
Previous alcohol abuse 979 495 (50.6)
Current alcohol abuse 979 266 (22.0)
Previous illicit drug use 979 369 (30.6)
Current illicit drug use 979 57 (4.7)
Previous smoking 979 442 (41.4)
Current smoking 979 299 (24.8)
* Total number of patients for whom information regarding risk
factors was available in medical records.
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RNA testing. Specific treatment for HCV had not yet been
prescribed for any patient when LF occurred.
The outcomes of the study population are showed in
Figure 1. Case definition for LF was met in 22.1% of
patients (223 of 1010) and of these, 5 died after LF.
Among the 1010 patients, 787 (77.9%) did not meet the
case definition of LF. Among these, 47.2% were dis-
charged after undetectable levels of HCV RNA, 88 of 787
(11.2%) were transferred to other facilities, and 25 (3.1%)
died. The median duration of follow-up for lost patients
was 4 months and 37.7% of those patients interrupted
care with less than 30 days after starting it.
According to univariate analysis, gender, absence of a
life partner, black race, psychiatric illness, and at least one
lifestyle risk factor were significantly associated with LF
(Table 2). Single black male patients were more likely to
experience LF. Among lifestyle factors, previous alcohol
abuse, previous and current illicit drug use, and previous
or current tobacco smoking were associated with LF.
In the multivariate analysis, absence of a life partner,
black race, psychiatric illness and substance abuse were
independently associated with LF (Table 3).
We were able to locate 104 (46.6%) of the 223 patients
lost to follow-up and only 33 (14.8%) returned to follow-up
Figure 1. Outcomes of the study population. LF:
lost to follow-up.
Table 2. Risk factors for loss to follow-up in univariate analysis.
Risk factor Patients lost to follow-up Patients in care No. of patients* P
Age (years) (mean±SD) 47.7 ± 10.8 48.5 ± 12.9 1010 0.3
Male, n (%) 141 (63.2) 416 (52.9) 1010 0.005
Absence of a life partner, n (%) 120 (55.6) 324 (41.8) 992 0.0003
Black race, n (%) 37 (17.3) 73 (9.4) 987 0.001
Comorbidities, n (%) 107 (56.9) 438 (58.0) 943 0.7
Diabetes, n (%) 20 (10.6) 116 (15.4) 943 0.09
Psychiatric illness, n (%) 40 (21.3) 86 (11.4) 943 0.0003
Lifestyle risk factors, n (%) 163 (79.9) 494 (63.7) 979 0.00001
Previous alcohol abuse, n (%) 122 (59.8) 373 (48.1) 979 0.003
Current alcohol abuse, n (%) 55 (27.0) 172 (22.2) 979 0.1
Previous illicit drug use, n (%) 93 (45.6) 244 (31.5) 979 0.0001
Current illicit drug use, n (%) 18 (8.8) 37 (4.4) 979 0.02
Previous smoking, n (%) 105 (51.5) 377 (43.5) 979 0.04
Current smoking, n (%) 75 (36.8) 195 (25.2) 979 0.0009
* Total number of patients for whom information regarding risk factors was available in medical records.
Table 3. Risk factors for loss to follow-up in multivariate analysis.
Risk factor Adjusted OR (95%CI) P
Male 1.16 (0.81–1.65) 0.41
Absence of life partner 1.44 (1.03–2.02) 0.02
Black race 1.80 (1.12–2.89) 0.01
Psychiatric illness 1.77 (1.14–2.73) 0.009
Diabetes 0.71 (0.4–1.21) 0.21
Any lifestyle risk factor* 1.95 (1.29–2.94) 0.001
* Lifestyle risk factors included previous or current alcohol abuse,
recreational drug use, and smoking.
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visits. The most frequent reason for LF stated by patients
was incompatibility between work hours and scheduled
clinical appointments, followed by incarceration (Table 4).
However, for 122 (54.7%) patients no reason for losing
follow-up could be provided.
Discussion
With recent advances in anti HCV treatment, SVR can
be reached in 80–90% of patients (7). In this new
scenario, it is now possible to envision a drastic reduction
of HCV prevalence, but major challenges remain. One of
them, according to our findings, is LF. Among anti-HCV-
positive patients, we found a LF rate of 22.1%, and male,
absence of a partner, black race and the presence of one
lifestyle risk factor were independently associated with LF.
In addition, almost 40% of patients were lost to follow-up
within less than one month after starting care. Finally, less
than 15% of patients lost to follow-up returned to the clinic
after being actively recalled.
There have been few studies evaluating LF and
non-adherence to care in the HCV infected population.
Notably, most data regarding non-adherence and patient
compliance are related to treatment-associated factors,
and are not regarded as a primary outcome (8–11).
For this reason, many patients who quit follow-up
before complete staging and treatment indication are not
included in those studies. Therefore, evaluating patient
adherence to care in the initial steps of HCV evaluation is
paramount for a more complete understanding of the
problem.
Before therapy has been indicated, treatment eligibility
is directly influenced by patient compliance with follow-up.
In Brazil, eligibility for treatment has been evaluated
in HIV/HCV co-infected patients and non-adherence
to therapy was found to be responsible for 31.4% of
ineligibility for HCV treatment (12). According to our find-
ings, patients are lost to follow-up soon after initiating care,
which has also been observed in previous studies (13,14).
A Greek study found that 27% of anti-HCV-positive were
lost to follow-up before HCV RNA testing, and the major-
ity of patients who did not receive treatment were lost
to follow-up (15). When evaluating LF as a risk factor
for treatment discontinuation and, similarly, for treat-
ment failure, observational studies have found that non-
adherence was directly associated with non-response to
therapy in 18 to 29% of patients (8,9,16–18). Our results
corroborate those findings and call attention to LF as an
important reason for treatment ineligibility.
Non-adherence to care is a known issue for chronic
illnesses. In terms of chronic, mostly asymptomatic infec-
tions, HIV and HCV share some similarities, especially
considering the need for close monitoring and follow-up.
In our cohort, the LF was similar to that observed around
the world among HIV-positive patients. Among HIV-positive
patients, the LF rates range from 13.4 to 25% (13,19–21).
In Brazil, among HIV-positive patients, the LF rates ranged
from 17.6 to 23.9% (22,23). The great variability observed
in HIV-positive populations can be related to the lack of
standardized definitions on follow-up time, which ranges
from 3 months in some studies to up to 12 months in
others (22,24–27). Secondly, the different population
characteristics in the various regions of the world that
could impact patients’ ability to consistently maintain
access to health care (28), can influence LF rates. It is
necessary to consider that these differences may also be
true for HCV infection.
Establishing risk factors associated with LF has the
potential to identify patients that require additional efforts
to remain in follow-up. Similar to our findings, previous
studies have also found a correlation between both alcohol
consumption and psychiatric illness with ineligibility for
treatment and also with treatment failures (10,12,29). The
association found between absence of a partner and LF is
difficult to be fully understood. A possible explanation
is that patients without partners do not possess sufficient
emotional and social support systems. Finally, a chronic
physical disease not only has direct consequences for the
patient, but can also disrupt the normal life of the healthy
partner (30).
According to the NHANES report, the HCV prevalence
is 14% among black people and 1.6% in the general
population in the USA, and black people with chronic
hepatitis C have higher age-adjusted mortality rates from
cirrhosis and CHC than non-Hispanic whites with chronic
hepatitis C (31). According to our findings, black race was
a recognizable risk factor for LF. It is possible that the high
rate of black patients who are lost to follow-up prior to
fibrosis staging and treatment indication may be respon-
sible for some of the high CHC incidence in this group,
and they might not be represented in studies of treatment
response.
In patients with hepatitis C, the association between
psychiatric disorders and LF is common. Patients infected
with HCV have a high prevalence (50%) of psychiatric
disease. In addition, the lifetime prevalence of psychosis,
Table 4. Reasons for loss to follow-up among 223 patients.
n (%)
Conflicts with work schedule 20 (9.0)
Incarceration 17 (7.6)
City relocation 15 (6.7)
Absence of symptoms 10 (4.5)
Recreational drugs abuse 9 (4.0)
Social condition 8 (3.6)
Alcohol abuse 7 (3.1)
Psychiatric disease 4 (1.8)
Others 11 (4.9)
Unknown 122 (54.7)
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anxiety, substance abuse, and personality disorders are
all higher among patients with HCV than the general USA
population (32). The association between lifestyle factors
(excess alcohol consumption, tobacco smoking or recrea-
tional drug use) could also be associated with impulsive
personality and hopelessness (33). In that sense, depres-
sion is the most commonly diagnosed mood disorder in
HCV-infected patients and has been extensively asso-
ciated with barriers to compliance with care and treatment
adherence (12,34–36).
We were able to locate only 46.6% of the patients lost
to follow-up. This finding suggests that efforts should be
made to encourage patients to provide as many personal
contacts as possible, and additional information on family
members or friends. In addition, for 54.7% of LF patients
no reason for non-compliance with care could be found.
This demonstrates that LF is a complex multifactorial
process and understanding patient-associated reasons for
non-compliance can present a challenge. Based on our
findings, we suggest that recalling patients is necessary
but not sufficient to ensure continuity of care. Similar
studies in the HIV-infected population showed that 4 to
28% of patients returned to care after recall (37,38).
Our study has some limitations. We were not able to
examine social characteristics, such as homelessness
and unemployment states because these variables were
not systematically reported in the medical records. Finally,
data on telephone number and name of primary care
physician were retrospectively collected after reviewing
patient’s charts, and might lack precision.
In conclusion, our study provides an estimated inci-
dence of LF among anti-HCV-positive patients and identi-
fies risk factors associated with this outcome. Importantly,
our results comprise LF data from patients at the first stage
in the HCV chain of care. In addition, our study can help
clinicians recognize patients at risk for non-compliance
and who require additional support for retention of care.
Longitudinal studies are urgently needed to better identify
these patients as well as variables that affect their retention
in care. A clear understanding of how patient characteristics
influence treatment adherence can assist the development
of better strategies to improve patient outcomes.
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